433 related articles for article (PubMed ID: 8643658)
1. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase.
Moro MA; Russel RJ; Cellek S; Lizasoain I; Su Y; Darley-Usmar VM; Radomski MW; Moncada S
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1480-5. PubMed ID: 8643658
[TBL] [Abstract][Full Text] [Related]
2. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.
Feelisch M; Kotsonis P; Siebe J; Clement B; Schmidt HH
Mol Pharmacol; 1999 Aug; 56(2):243-53. PubMed ID: 10419542
[TBL] [Abstract][Full Text] [Related]
3. Effect of selective inhibition of soluble guanylyl cyclase on the K(Ca) channel activity in coronary artery smooth muscle.
Li PL; Jin MW; Campbell WB
Hypertension; 1998 Jan; 31(1 Pt 2):303-8. PubMed ID: 9453320
[TBL] [Abstract][Full Text] [Related]
4. Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation.
Olson LJ; Knych ET; Herzig TC; Drewett JG
Hypertension; 1997 Jan; 29(1 Pt 2):254-61. PubMed ID: 9039111
[TBL] [Abstract][Full Text] [Related]
5. Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock.
Zingarelli B; Haskó G; Salzman AL; Szabó C
Crit Care Med; 1999 Sep; 27(9):1701-7. PubMed ID: 10507586
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide attenuates endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 in vascular smooth muscle cells by a cGMP-dependent pathway.
Bouallegue A; Daou GB; Srivastava AK
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2072-9. PubMed ID: 17644565
[TBL] [Abstract][Full Text] [Related]
7. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
Garthwaite J; Southam E; Boulton CL; Nielsen EB; Schmidt K; Mayer B
Mol Pharmacol; 1995 Aug; 48(2):184-8. PubMed ID: 7544433
[TBL] [Abstract][Full Text] [Related]
8. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase.
Olesen SP; Drejer J; Axelsson O; Moldt P; Bang L; Nielsen-Kudsk JE; Busse R; Mülsch A
Br J Pharmacol; 1998 Jan; 123(2):299-309. PubMed ID: 9489619
[TBL] [Abstract][Full Text] [Related]
9. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles.
Sobey CG; Faraci FM
Stroke; 1997 Apr; 28(4):837-42; discussion 842-3. PubMed ID: 9099205
[TBL] [Abstract][Full Text] [Related]
10. In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway.
Fedele E; Jin Y; Varnier G; Raiteri M
Br J Pharmacol; 1996 Oct; 119(3):590-4. PubMed ID: 8894183
[TBL] [Abstract][Full Text] [Related]
11. Effects of a novel guanylate cyclase inhibitor on nitric oxide-dependent inhibitory neurotransmission in canine proximal colon.
Franck H; Sweeney KM; Sanders KM; Shuttleworth CW
Br J Pharmacol; 1997 Nov; 122(6):1223-9. PubMed ID: 9401790
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide inhibits aldosterone synthesis by a guanylyl cyclase-independent effect.
Hanke CJ; Drewett JG; Myers CR; Campbell WB
Endocrinology; 1998 Oct; 139(10):4053-60. PubMed ID: 9751482
[TBL] [Abstract][Full Text] [Related]
13. The effect of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide.
Onoue H; Katusic ZS
Brain Res; 1998 Feb; 785(1):107-13. PubMed ID: 9526059
[TBL] [Abstract][Full Text] [Related]
14. Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation.
Nimmegeers S; Sips P; Buys E; Brouckaert P; Van de Voorde J
Cardiovasc Res; 2007 Oct; 76(1):149-59. PubMed ID: 17610859
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease.
Riddell DR; Graham A; Owen JS
J Biol Chem; 1997 Jan; 272(1):89-95. PubMed ID: 8995232
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism: relationship to microfilament dissociation and altered cell morphology.
Brown C; Pan X; Hassid A
Circ Res; 1999 Apr; 84(6):655-67. PubMed ID: 10189353
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets.
Tsikas D; Ikic M; Tewes KS; Raida M; Frölich JC
FEBS Lett; 1999 Jan; 442(2-3):162-6. PubMed ID: 9928994
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
[TBL] [Abstract][Full Text] [Related]
20. cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide.
Vaziri ND; Wang XQ
Hypertension; 1999 Dec; 34(6):1237-41. PubMed ID: 10601124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
